A Study of miRNA 371 in Patients With Germ Cell Tumors
This trial studies whether the blood marker micro ribonucleic acid (miRNA) 371 can predict
the chance of cancer returning in patients with germ cell cancers. Studying samples of blood
from patients with germ cell cancers in the laboratory may help doctors predict how likely
the cancer will come back.
Intervention
Biomarker Analysis, Blood Product Collection
Condition
Germ Cell Tumor, Metachronous Malignant Neoplasm, Seminoma, Stage I Testicular Cancer AJCC v8, Stage IA Testicular Cancer AJCC v8, Stage IB Testicular Cancer AJCC v8, Stage IS Testicular Cancer AJCC v8
Investigators
Craig R Nichols, Jay W. Carlson, Lisa Bailey, Brian R. Hu, Kendrith M. Rowland, Bryan A. Faller, Mark F. Kozloff, Nabil Adra, Preston D. Steen, Paul M. Barr, Christopher H. Chay, Timothy D. Moore, Abdul Hai Mansoor, Christopher W. Ryan, Rubina Qamar, Edward P. Gelmann, Frederick E. Millard, Siamak Daneshmand, Cory Hugen, Jeffrey L. Berenberg, Scott E. Delacroix, Bruce J. Roth, Thomas L. Jang, Nancy B. Davis, Andrea L. Harzstark, Shilajit Kundu, Bret E. Friday, Thomas P. Bradley, John A. Ellerton, Nicholas G. Cost, Abhinav Sidana, Lucia Nappi, Kimberly M. Hagel, Rohan Garje, Kathleen J. Yost, Sunil Parimi, Helen H. Moon, Mark S. Litwin, Scott E. Eggener, Neda Hashemi Sadraei, Kelly L. Stratton, Asit K. Paul, Ahmad Shabsigh, Natasha M. Tiffany, Anupam Batra, Seth O. Fagbemi, Joshua Lukenbill, John C. Henegan, Benjamin A. Teply, Ki Y. Chung, Yair Lotan, Huong T. Pham, Naveen S. Basappa, Daygen Finch, Lori A. Wood, Robert J. Hamilton, Isaac A. Bowman, Matthew L. Ryan